Biotech | September 23, 2021
Aurobindo subsidiary submits MAA for oncology biosimilar
CuraTeQ Biologics is on track for filing a second oncology biosimilar
CuraTeQ Biologics is on track for filing a second oncology biosimilar
These aprons utilise phase change materials that absorb, store and release heat for optimal thermal comfort
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
The CASPIAN Phase III trial in extensive-stage small-cell lung cancer is the longest survival follow-up ever reported for immunotherapy treatment in this setting
_256_384.jpg)
The council has also reduced the GST to 5 per cent on a few more Covid-19 medicines
If approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC
The recommendation is based on positive results from the pivotal Phase 3 CheckMate -649 trial in which Opdivo plus chemotherapy demonstrated superior overall survival versus chemotherapy
They enter into exclusive negotiations in a new drive to create a technology-driven leader for complex small molecules and ADCs of global scale
Barbara Engelhardt moves her computational and statistics lab to Gladstone
It approves tissue-based NGS companion diagnostic for Takeda's targeted therapy for NSCLC patients with EGFR Exon20 insertion mutations
Subscribe To Our Newsletter & Stay Updated
